Improving the efficacy of cellular therapies

Published in Nature Communications, the new study was directed by Dr. Marie-Ève Lebel, a post-doctoral intern at the Maisonneuve-Rosemont Hospital Research Centre, which is part of the Centre intégré universitaire de santé et de services sociaux de l'Est-de-l'Île-de-Montréal (CIUSSS-EMTL).

Ms. Lebel works in the laboratory of Dr. Heather Melichar, a researcher at CR-HMR and assistant professor in the Department of Microbiology, Infectiology and Immunology at Université de Montreal.

Carried out in collaboration with researchers at the Lady Davis Institute of McGill University and at Harvard University, Lebel's work promises to improve the efficacy of cell therapy.

T cells are an important component of the immune system, which allows the body to be protected against infections, as well as contributing to eliminating cancer cells that are recognized as being foreign to the organism.

The use of the immune system to destroy tumour cells, called immunotherapy, has not only allowed for an increase in the survival rate of cancer patients, but has also meant a cure for patients with advanced stage cancer and/or those patients for whom traditional therapies have failed.

Nevertheless, several obstacles can hinder the efficacy of immunotherapy due to T cell tolerance mechanisms that produce a state of immune non-response to a specific antigen. Lebel has focused on understanding these tolerance mechanisms in order to counteract the inability of certain T cells to attack diseased cells.

She and her colleagues have been able to identify certain factors that influence the development of T cells by better understanding the environment in which they develop and the interaction between cells.

Ultimately, these elements have a major impact on the body´s capacity to control an infectious agent, or even the growth of tumour cells.

"This discovery is a powerful scientific breakthrough, as these results will help us identify new targets and approaches to increase the anti-cancer activity of T cells in order to improve the survival of our patients," said Dr. Denis Claude Roy, director of the Institut universitaire en hémato-oncologie et en thérapie cellulaire (IUHOTC) and the Centre d'excellence en thérapie cellulaire (CETC) Maisonneuve-Rosemont Hospital, in Montreal.